Avenue Therapeutics, Inc.

NasdaqCM ATXI

Avenue Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

Avenue Therapeutics, Inc. Net Cash Used For Investing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Avenue Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3.00 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqCM: ATXI

Avenue Therapeutics, Inc.

CEO	Dr. Alexandra MacLean M.D.
IPO Date	June 27, 2017
Location	United States
Headquarters	1140 Avenue of the America
Employees	3
Sector	Health Care
Industries Pharmaceuticals

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Key trends

Past 5 years